

Consolidated Financial Statements

June 30, 2022

(With Independent Auditors' Reports Thereon)

Table of Contents

	Page(s)
Independent Auditors' Report	1–3
Consolidated Balance Sheet	4
Consolidated Statement of Activities and Changes in Net Assets	5
Consolidated Statement of Cash Flows	6
Notes to Consolidated Financial Statements	7–34
Appendix A - Schedule of Financial Responsibility Data	35
Independent Auditors' Report on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance With <i>Government Auditing Standards</i>	36–37



KPMG LLP Suite 1900 440 Monticello Avenue Norfolk, VA 23510

Independent Auditors' Report

The Board of Visitors Eastern Virginia Medical School:

Report on the Audit of the Consolidated Financial Statements

Opinion

We have audited the consolidated financial statements of Eastern Virginia Medical School and Affiliated Organization (EVMS), which comprise the consolidated balance sheet as of June 30, 2022, and the related consolidated statements of activities and changes in net assets, and cash flows for the year then ended, and the related notes to consolidated financial statements.

In our opinion, the accompanying consolidated financial statements present fairly, in all material respects, the consolidated financial position of the EVMS as of June 30, 2022, and the changes in its net assets and its cash flows for the year then ended in accordance with U.S. generally accepted accounting principles.

We did not audit the financial statements of Eastern Virginia Medical School Foundation (EVMS Foundation), for which EVMS records a beneficial interest in net assets, which statements reflect total assets constituting 27.95 percent of consolidated total assets at June 30, 2022, and total revenues constituting 3.45 percent of consolidated total revenues for the year then ended. Those statements were audited by other auditors, whose report has been furnished to us, and our opinion, insofar as it relates to the amounts included for EVMS Foundation, is based solely on the report of the other auditors.

Report on Summarized Comparative Information

We have previously audited EVMS' 2021 consolidated financial statements, and we expressed an unmodified audit opinion on those audited consolidated financial statements in our report dated October 26, 2021. In our opinion, the summarized comparative information presented herein as of and for the year ended June 30, 2021, is consistent, in all material respects, with the audited consolidated financial statements from which it has been derived.

Basis for Opinion

We conducted our audit in accordance with auditing standards generally accepted in the United States of America (GAAS) and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States. Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are required to be independent of EVMS and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with U.S. generally accepted accounting principles, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.



In preparing the consolidated financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about EVMS' ability to continue as a going concern for one year after the date the consolidated financial statements are available to be issued.

Auditors' Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS and *Government Auditing Standards* will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the consolidated financial statements.

In performing an audit in accordance with GAAS and Government Auditing Standards, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are
 appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of
 EVMS' internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the consolidated financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about EVMS ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control related matters that we identified during the audit.

Supplementary Information

Our audit was conducted for the purpose of forming an opinion on the consolidated financial statements as a whole. The accompanying supplementary schedule of financial responsibility data is presented for purposes of additional analysis as required by the U.S. Department of Education, and is not a required part of the consolidated financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements and certain additional procedures applied in the audit of the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the consolidated financial statements or to the consolidated financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the supplementary schedule of financial responsibility data is fairly stated, in all material respects, in relation to the consolidated financial statements as a whole.



Other Reporting Required by Government Auditing Standards

In accordance with *Government Auditing Standards*, we have also issued our report dated October 28, 2022 on our consideration of EVMS' internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements and other matters. The purpose of that report is solely to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion on the effectiveness of EVMS' internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering EVMS' internal control over financial reporting and compliance.



Norfolk, Virginia October 28, 2022

Consolidated Balance Sheet

June 30, 2022

(With summarized financial information as of June 30, 2021)

Assets	2022	2021
Current assets:		
Cash and cash equivalents		124,504,652
Restricted cash and investments Operating investments	9,228,159 17,509,494	9,223,700 21,093,703
Accounts receivable, net	30,613,905	24,862,209
Accounts receivable from affiliate	1,566,449	230,784
Current portion of notes receivable from students	369,900	977,400
Prepaid expenses and other current assets	2,865,647	2,826,052
Total current assets	192,784,615	183,718,500
Property, plant, and equipment, net Other long-term assets:	205,488,323	200,372,653
Operating investments	18,804,183	17,980,617
Notes receivable from students	2,314,507	1,965,813
Interest in net assets of affiliate Other long-term assets	164,355,934 4,255,384	179,232,604 4,200,428
Total other long-term assets	189,730,008	203,379,462
Total assets \$	588,002,946	587,470,615
Liabilities and Net Assets		
Liabilities:		
Current liabilities:		
Current portion of long-term debt	, ,	2,870,369
Accounts payable Accrued compensation	7,684,140 17,954,105	7,553,971 17,693,205
Deferred income	5,692,788	5,731,632
Accrued expenses and other current liabilities	10,926,638	9,736,490
Total current liabilities	45,201,175	43,585,667
Long-term debt, excluding current portion and net of bond issuance costs	35,381,418	36,169,761
Other long-term liabilities:	00,001,110	00,100,101
Grant deposits	1,402,174	2,054,042
Refundable federal student loans	2,027,860	2,475,304
Assets held for affiliate	980,336	962,068
Other long-term liabilities	7,225,082	6,943,858
Total other long-term liabilities	11,635,452	12,435,272
Total liabilities	92,218,045	92,190,700
Net assets: Net assets without donor restrictions:		
Operating	10,254,326	9,767,579
EVMS reserves	73,821,817	74,857,336
Department reserves	101,236,607	86,255,270
Net investment in plant	38,456,678	32,324,690
Sponsored research	740,051	419,114
Parking facility reserves	746,037	690,949
Total net assets without donor restrictions	225,255,516	204,314,938
Net assets with donor restrictions:	074 400	007 500
Revolving student loans	874,409	987,523
Program restricted	665,065	638,745
Net investment in plant Interest in net assets of affiliate	104,633,977 164,355,934	110,106,105 179,232,604
Total net assets with donor restrictions		290,964,977
Total net assets	<u>270,529,385</u> 495,784,901	495,279,915
Commitments and contingencies	-30,104,301	730,273,310
Total liabilities and net assets	588,002,946	587,470,615
	000,002,040	001,110,010

See accompanying notes to consolidated financial statements.

Consolidated Statement of Activities and Changes in Net Assets

Year ended June 30, 2022 (With summarized financial information for the year ended June 30, 2021)

	Net assets without donor restrictions	Net assets with donor restrictions	Total	2021
Operating revenues and support:				
Tuition and fees	\$ 47,434,358	_	47,434,358	47,412,850
State appropriations	30,999,226	520,450	31,519,676	53,092,329
Municipal subsidies	1,333,980	_	1,333,980	1,331,460
Federal grants and contracts	21,912,133	_	21,912,133	18,966,602
State grants and contracts	1,322,257	_	1,322,257	474,409
Private grants, contracts, and gifts	3,148,211	_	3,148,211	2,379,500
EVMS Foundation support	9,398,002	_	9,398,002	7,995,323
Patient care services	58,200,302	—	58,200,302	61,737,508
Contractual services of graduate school residents	43,811,929	_	43,811,929	41,519,019
Contractual services	34,402,538	—	34,402,538	37,646,840
Sales and services of auxiliary enterprises	6,168,326	—	6,168,326	6,688,140
Other sources	11,295,051	508,468	11,803,519	9,600,337
Interest and investment income	1,113,373	11,481	1,124,854	1,019,176
Released from restriction	6,599,321	(6,599,321)		
Total operating revenues and support	277,139,007	(5,558,922)	271,580,085	289,863,493
Operating expenses:				
Undergraduate instruction	62,767,499	—	62,767,499	59,561,504
Graduate instruction	32,566,350	_	32,566,350	30,223,320
Research	23,296,367	_	23,296,367	20,217,440
Patient services	62,263,853	_	62,263,853	69,381,779
Academic support	10,203,770	—	10,203,770	9,709,539
Institutional support	29,959,725	—	29,959,725	25,451,105
Auxiliary services	25,336,791	—	25,336,791	23,572,474
Patient services support	8,464,612		8,464,612	8,689,171
Total operating expenses	254,858,967		254,858,967	246,806,332
Changes in net assets from operations	22,280,040	(5,558,922)	16,721,118	43,057,161
Nonoperating items:				
Unrealized (losses) gains from investments, net	(2,977,259)	—	(2,977,259)	270,700
Change in interest of net assets of affiliate	—	(14,876,670)	(14,876,670)	48,364,775
Change in fair value of interest rate swaps	1,637,797		1,637,797	1,115,896
Changes in net assets	20,940,578	(20,435,592)	504,986	92,808,532
Net assets at beginning of year	204,314,938	290,964,977	495,279,915	402,471,383
Net assets at end of year	\$ 225,255,516	270,529,385	495,784,901	495,279,915

See accompanying notes to consolidated financial statements.

Consolidated Statement of Cash Flows

Year ended June 30, 2022

(With summarized financial information for the year ended June 30, 2021)

	-	2022	2021
Cash flows from operating activities:			
Changes in net assets	\$	504,986	92,808,532
Adjustments to reconcile changes in net assets to net cash provided by operating activities:			
Depreciation and amortization		12,396,594	11,811,806
Change in fair value of interest rate swaps		(1,637,797)	(1,115,896)
Net realized and unrealized losses (gains) on investments		2,977,259	(269,246)
Change in interest of net assets of affiliate		14,876,670	(48,364,775)
Net loss (gain) on sale of property, plant, and equipment		2,961	(129,532)
Provision for bad debts		127,004	135,848
Amortization of bond issuance costs		26,636	28,070
Restricted contributions for property, plant, and equipment		(1,243,094)	(23,613,675)
Changes in:			
Accounts receivable, net		(5,751,698)	(3,758,990)
Accounts receivable from affiliate		(1,335,665)	354,423
Prepaid expenses and other current assets		(39,595)	67,102
Other long-term assets		(2,400)	(2,400)
Accounts payable		130,169	(4,060,584)
Accrued compensation		260,900	6,592,994
Deferred income		(38,844)	2,396,734
Accrued expenses and other current liabilities		1,190,150	244,390
Grant deposits		(651,868)	213,032
Assets held for affiliate		18,268	14,982
Other long-term liabilities	-	281,224	1,491,169
Net cash provided by operating activities	-	22,091,860	34,843,984
Cash flows from investing activities:			
Purchases of restricted investments		(748,182)	(1,277,184)
Proceeds from sales and maturities of restricted investments		819,147	263,011
Purchases of operating investments		(16,397,769)	(14,799,887)
Proceeds from sales and maturities of operating investments		16,181,153	14,407,668
Purchases of property, plant, and equipment		(17,584,115)	(28,944,818)
Proceeds from sale of property, plant, and equipment		68,890	205,558
Disbursements for notes receivable from students		(377,735)	(320,000)
Collections of notes receivable from students		509,536	1,077,670
Change in cash surrender value of life insurance	-	(52,556)	(151,984)
Net cash used in investing activities	-	(17,581,631)	(29,539,966)
Cash flows from financing activities:			
Restricted contributions for property, plant, and equipment		1,243,094	23,613,675
Proceeds from long-term borrowings		3,766,321	3,424,765
Payments for bond issuance costs		—	(70,000)
Principal payments on bonds		(2,870,368)	(2,735,000)
Refundable federal student loans	-	(447,444)	(456,065)
Net cash provided by financing activities	-	1,691,603	23,777,375
Net increase in cash, cash equivalents, and restricted cash		6,201,832	29,081,393
Cash, cash equivalents, and restricted cash at beginning of year	_	129,383,511	100,302,118
Cash, cash equivalents, and restricted cash at end of year	\$	135,585,343	129,383,511
Supplemental disclosures of cash flow information:	-		
Cash paid for interest, net of amounts capitalized	\$	1,086,168	736,523
Purchases of property, plant, and equipment included in accounts payable	Ψ	1,875,751	1,623,537
		.,,	.,020,007

See accompanying notes to consolidated financial statements.

Notes to Consolidated Financial Statements

June 30, 2022 (With summarized financial information as of June 30, 2021)

(1) EVMS and Affiliated Organization

The Eastern Virginia Medical School (EVMS or the School) was created in 1964 by enabling legislation of the General Assembly of Virginia to identify, document, and evaluate needs, problems, and resources relating to health and medical care within its service area and to plan, develop, and implement programs to meet such needs on both an immediate and long-range basis. EVMS may plan, design, construct, remove, enlarge, equip, maintain, and operate medical educational institutions and medical and paramedical facilities, together with related and supporting facilities, and do all things necessary and convenient to carry out any of its purposes. EVMS' powers also include the right of eminent domain within the City of Norfolk and the authorization to borrow funds and issue bonds. EVMS has been classified as an organization described in Section 501(c)(3) of the Internal Revenue Code (IRC). As such, EVMS is exempt from federal and state income taxation, and contributions to it are tax deductible.

EVMS Medical Group (EVMS MG) is a nonmember organization incorporated under the Virginia Nonstock Corporation Act. Prior to July 1, 1989, EVMS MG was an operating division of EVMS. Effective July 1, 1989, EVMS MG began operations as a not-for-profit foundation through the approval of EVMS MG's Articles of Incorporation and Bylaws by the EVMS Board of Visitors. EVMS MG bylaws cannot be altered or amended without the approval of the EVMS Board of Visitors. EVMS MG has been classified as an organization described in Section 501(c)(3) of the IRC and is exempt from federal and state income taxation. The accounts of EVMS MG are included in the accompanying consolidated financial statements.

The Eastern Virginia Medical School Foundation (EVMS Foundation) is a nonprofit organization established to provide financial support to EVMS. The EVMS Foundation qualifies as a charitable foundation and is exempt from federal and state income taxation under Section 501(c)(3) of the IRC. As such, contributions to it are tax deductible. The accounts of EVMS Foundation are not included in the accompanying consolidated financial statements of EVMS. Amounts received from the EVMS Foundation are reported as EVMS Foundation support in the accompanying consolidated statement of activities and changes in net assets. EVMS' beneficial interest in the net assets of EVMS Foundation of \$164,355,934 and \$179,232,604 as of June 30, 2022 and 2021, respectively, is presented as interest in net assets of affiliate within net assets with donor restrictions. Once the funds have met their donor-imposed restrictions and are remitted to EVMS, they are reported as net assets without donor restrictions. Changes in the interest of the net assets of EVMS Foundation are included in nonoperating items on the accompanying consolidated statement of activities. During the years ended June 30, 2022 and 2021, income from the EVMS Foundation of \$9,398,002 and \$7,995,323, respectively, is presented in operating revenues and support on the accompanying consolidated statement of activities and changes in net assets.

EVMS has defined its mission as a community-based academic institution dedicated to medical and health education, research, and patient care.

(a) Education

Undergraduate Education – Opened in 1973, EVMS offers a Doctor of Medicine (M.D.) degree. In 2012, the Association of American Medical Colleges' Liaison Committee on Medical Education awarded EVMS continued full accreditation of the educational program leading to the M.D. degree. Renewal of this accreditation was completed in February 2021 giving EVMS full accreditation of the medical education program for an eight-year term.

Notes to Consolidated Financial Statements

June 30, 2022 (With summarized financial information as of June 30, 2021)

In 2009, the Southern Association of Colleges and Schools Commission on Colleges (SACSCOC) awarded EVMS a continuation of accreditation for a 10-year period. EVMS received notice on January 12, 2022 that the SACSCOC Board of Trustees reaffirmed accreditation through 2030.

EVMS also offers several health professions programs, including master's degrees in art therapy, public health, physician assistant, clinical embryology, lab animal science, medical master's, surgical assistant, biotechnology and biomedical sciences, and doctoral degrees in health sciences, medical and professional education, reproductive clinical sciences, clinical psychology, and biomedical sciences in conjunction with other local universities.

Graduate Medical Education (GME) – Founded in 1974, GME offers residency and fellowship programs at numerous healthcare facilities in EVMS' service area. Programs are accredited by the Accreditation Council of Graduate Medical Education or the American Psychological Association or are approved by specialty boards.

(b) Research

EVMS conducts numerous research projects in various areas, including proteomics, cancer, reproductive medicine, systemic diseases, and infectious diseases. EVMS-sponsored research is supported by various federal and state agencies, pharmaceutical companies, and private foundations.

(c) Patient Care

Clinical care is provided through the following affiliates:

EVMS MG – EVMS MG was formed exclusively for charitable, scientific, and educational purposes and to further the mission and goals of EVMS. EVMS MG is organized and shall at all times operate to fulfill its corporate purpose by supporting clinical practice and research in conjunction with providing faculty the opportunity to teach in a physician group practice setting within the academic environment of EVMS. EVMS MG also provides education and training to EVMS students and residents. EVMS MG incorporates the professional practice units of the EVMS faculty in all departments except pediatrics. The practice units are staffed solely by faculty members of EVMS who provide professional patient care at EVMS facilities or through agreements with other area hospitals.

EVMS Pediatrics, formerly Pediatric Faculty Associates, Inc. (PFA) – PFA was established through an affiliation agreement between EVMS, Children's Hospital of the King's Daughters (CHKD), and Children's Health System, Inc. During fiscal year 1998, PFA underwent significant organizational and structural changes. A majority of the full-time faculty members in the pediatric specialties established a for-profit professional limited liability company, Children's Specialty Group, PLLC (CSG). On June 30, 2008, the PFA corporate status was dissolved. All assets and liabilities were transferred to EVMS and reported as EVMS Pediatrics.

EVMS Pediatrics, along with CSG, incorporates the professional practice units of the EVMS faculty in the pediatric specialties. They provide professional patient care at EVMS or CHKD facilities or through agreements with other area hospitals on a contractual basis.

Notes to Consolidated Financial Statements

June 30, 2022 (With summarized financial information as of June 30, 2021)

(2) Summary of Significant Accounting Policies

(a) Basis of Presentation and Consolidation

EVMS' consolidated financial statements have been prepared on the accrual basis of accounting. All intercompany balances and transactions have been eliminated in consolidation. These consolidated financial statements have been prepared to focus on EVMS as a whole and to present balances and transactions according to the existence or absence of donor-imposed restrictions. Resources are classified based on the existence or absence of donor-imposed restrictions and are segregated into two net asset groups as follows:

Net assets without donor restrictions – Net assets that are not subject to donor-imposed stipulations. Net assets without donor restrictions are those net assets that are the result of revenues and income minus expenses and are grouped by operating, EVMS reserves, department reserves, net investment in plant, sponsored research, and the parking facility. Designated net assets are reported on the balance sheet as EVMS reserves and department reserves and represent net assets that are subject to self-imposed limits by action of management, as delegated by the governing board.

Net assets with donor restrictions – Net assets subject to donor-imposed stipulations that may or will be met by actions of EVMS and/or the passage of time. The interest in net assets of affiliate is restricted by time, while the remaining net assets with donor restrictions are restricted by purpose.

Revenues are reported as increases in net assets without donor restrictions unless use of the related assets is limited by donor-imposed restrictions. Expenses are reported as decreases in net assets without donor restrictions. Gains and losses on investments and other assets or liabilities are reported as increases or decreases in net assets without donor restrictions or net assets with donor restrictions. Expirations of temporary restrictions on net assets (i.e., the donor-stipulated purpose has been fulfilled and/or the stipulated time period has elapsed) are reported as net assets released from restriction in the consolidated statement of activities and changes in net assets. Contributions, including unconditional promises to give, are recognized as revenue in the period received. Contributions for acquisition or construction of plant facilities are released from restrictions in the period in which the assets are placed in service, unless the donor specifies the asset must be used for a specified period of time. Contributions that impose restrictions that are met in the same fiscal year they are received are reported as increases in net assets without donor restrictions.

Notes to Consolidated Financial Statements

June 30, 2022 (With summarized financial information as of June 30, 2021)

Designated net assets without donor restrictions contained within EVMS reserves and department reserves at June 30 are as follows:

	_	2022	2021
EVMS reserves:			
President and institutional development	\$	65,152,216	65,153,995
Faculty development		641,282	748,791
Internal research		625,422	785,655
Strategic planning		7,402,897	8,026,407
Academic student information	_		142,488
Total EVMS reserves	_	73,821,817	74,857,336
Department reserves:			
Insurance and legal reserves		18,066,632	17,532,120
Faculty development		20,018,777	14,015,854
Internal research		12,384,314	12,789,728
President and institutional development		5,914,287	6,478,789
Chairman's fund		5,121,856	5,530,474
Facilities and equipment		5,937,212	5,812,072
Strategic planning		2,193,276	3,084,938
Resident education		3,528,487	3,125,864
Student fees		2,344,467	2,144,612
Other		8,442,412	5,841,965
Physician supplemental payment program – EVMS MG		7,751,171	4,834,218
Unallocated nonsalary physician compensation – EVMS MG		6,539,264	2,234,338
Operating reserve – EVMS MG	_	2,994,452	2,830,298
Total department reserves	_	101,236,607	86,255,270
Total designated net assets without donor restrictions	\$_	175,058,424	161,112,606

The consolidated financial statements include certain prior year summarized comparative information in total but not by net asset class. Such information does not include sufficient detail to constitute a presentation in conformity with U.S. generally accepted accounting principles (GAAP). Accordingly, such information should be read in conjunction with EVMS' consolidated financial statements as of and for the year ended June 30, 2021, from which the summarized information was derived.

(b) Cash and Cash Equivalents

EVMS considers all highly liquid investments with original maturities of three months or less when purchased to be cash equivalents for consolidated financial statement presentation. Cash and cash equivalents that are managed by EVMS' investment managers as part of its long-term investment portfolio are reported within operating investments on the consolidated balance sheet. Cash equivalents consist primarily of temporary investments in money market funds and bank repurchase agreements.

Notes to Consolidated Financial Statements

June 30, 2022 (With summarized financial information as of June 30, 2021)

(c) Restricted Cash and Investments

Restricted cash and investments represent funds that have been externally restricted or internally designated for a specific purpose and are reported on the consolidated balance sheet at fair value.

The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated balance sheet that sum to the total of the same such amounts shown in the consolidated statement of cash flows:

	-	2022	2021
Cash and cash equivalents	\$	130,631,061	124,504,652
Restricted cash included in assets restricted to revolving			
student loans		1,561,589	1,731,150
Restricted cash included in assets restricted to parking facility	_	3,392,693	3,147,709
	\$_	135,585,343	129,383,511

Assets restricted to revolving student loans on the consolidated balance sheet include cash received with a donor-imposed restriction that limits use of that cash to refundable federal loans and refundable institutional loans. Assets restricted to parking facility include cash received for the parking consortium.

(d) Operating Investments

Investments are classified as trading and are reported on the consolidated balance sheet at fair value. Net realized gains and losses on investments are reflected in operating revenues and support in the accompanying consolidated statement of activities. Net unrealized gains and losses on investments are reflected in nonoperating items in the accompanying consolidated statement of activities and changes in net assets. The current year gains and losses on investments have been recognized in the accompanying consolidated statement of activities and changes in net assets as increases or decreases in net assets without donor restrictions, unless their use is restricted by explicit donor stipulations.

(e) Patient Accounts Receivable

Patient accounts receivable consist of patient receivables and is recorded net of allowances for discounts, implicit and explicit price concessions. Accounts receivable also includes contracts receivable, which represents amounts due from various healthcare entities for services provided.

(f) Property, Plant, and Equipment

Property, plant, and equipment are stated at cost or at estimated fair value at date of gift if acquired by gift. Depreciation is computed using the straight-line method over the estimated useful lives of the property, plant, and equipment.

Notes to Consolidated Financial Statements

June 30, 2022 (With summarized financial information as of June 30, 2021)

The estimated useful lives are as follows:

Land improvements	5–20 years
Buildings and improvements	5–40 years
Equipment	3–20 years

(g) Other Long-Term Assets

Other long-term assets in the accompanying consolidated balance sheet primarily comprise cash surrender value of life insurance policies held by EVMS MG.

EVMS MG is the owner of two insurance policies for current and retired faculty of EVMS, where EVMS MG is the beneficiary. These policies are recorded at their net cash surrender values, as reported by the issuing insurance company, whose Standard & Poor's financial strength rating is AA+. The net cash surrender values totaled \$4,119,126 and \$4,066,570 as of June 30, 2022 and 2021, respectively.

The cash surrender value of life insurance is valued under Level 2 of the fair value hierarchy at June 30, 2022 and 2021. The cash surrender value of life insurance was determined by the underwriting insurance company's valuation models, which take into account the passage of time, mortality tables, interest rates, cash values for paid-up additions, and dividend accumulations. The cash surrender value represents the guaranteed value EVMS MG would receive upon surrender of these policies held on key employees as of June 30, 2022.

(h) Refundable Federal Student Loans

Funds provided by the U.S. government under the Federal Perkins and Health Professions Student Loan Programs are loaned to qualified students and may be reloaned after collections. These funds are ultimately refundable to the government and are reported as liabilities in the accompanying consolidated balance sheet. Due to the dissolution of the Perkins Loan program, no new Perkins Loans were disbursed during the year ended June 30, 2022.

(i) Tuition and Fees

Student tuition and fees are recognized as revenue over time as the related academic services are provided. Student tuition and fees received in advance of services to be rendered are recorded as deferred income. Student aid provided by EVMS for tuition and fees is reflected as a reduction of tuition and fee revenue. EVMS had \$5,588,683 and \$5,627,527 of deferred tuition and fees as of June 30, 2022 and 2021, respectively that will be recognized in the subsequent fiscal year when the programs occur.

(j) Sponsored Grants and Contracts

EVMS is awarded grants, contracts, and similar agreements by federal, state, and private sponsoring organizations. Nonreciprocal transactions generally contain restrictions, by sponsors, for certain purposes and are recognized as revenue when EVMS has met the conditions of the agreements. EVMS has elected the simultaneous release policy, which allows a not-for-profit organization to report as

Notes to Consolidated Financial Statements

June 30, 2022 (With summarized financial information as of June 30, 2021)

without donor restrictions donor-restricted contributions whose restrictions are met in the same period as the revenue is recognized. In accordance with Topic 606, revenue from exchange grants and contracts is recognized as EVMS meets the performance obligations contained in the agreement with the sponsor or services are rendered. The majority of revenues from sponsored grants and contracts include facilities and administration cost recovery reimbursement from the federal government and are recognized when allowable expenditures are incurred.

(k) Patient Care Services

Patient care services revenue is reported at the amount that reflects the consideration to which EVMS MG expects to be entitled in exchange for providing patient care. These amounts are due from patients, third-party payors (including health insurers and government programs), and others, and includes variable consideration for retroactive revenue adjustments due to settlements of audits, reviews, and investigations.

EVMS MG has agreements with various Health Maintenance Organizations (HMOs) to provide medical services to subscribing participants. The HMOs generally make fee-for-service payments to EVMS MG for certain covered services based upon discounted fee schedules.

(I) Charity Care

EVMS MG provides care to patients who meet certain criteria under its charity care policy without charge or at amounts less than its established rates. Because EVMS MG does not pursue collection of amounts determined to qualify as charity care, they are not reported as revenue in the accompanying consolidated statement of activities.

EVMS MG maintains detailed records to identify and monitor the level of charity care it provides to its patients. These records include the amount of charges foregone and estimated direct and indirect costs incurred for services furnished under its charity care policy. Costs incurred are estimated based on the ratio of total operating expenses to gross charges applied to charity care charges. The following information measures the level of charity care provided during the years ended June 30:

	2022	2021
Charges foregone, based on established rates \$	557,632	586,565
Estimated costs incurred	292,664	298,680

(m) Contractual Services of Graduate School Residents

EVMS provides services for administering internships, residency, and fellowship programs to hospitals and healthcare facilities in EVMS' service area. Services are provided on a contractual basis at annually negotiated rates. EVMS manages the schedules for residents at the healthcare facilities and incurs payroll costs for the residents. Revenues are recognized over time as the related services are provided to the healthcare facilities.

Notes to Consolidated Financial Statements

June 30, 2022 (With summarized financial information as of June 30, 2021)

(n) Contractual Services

EVMS provides standardized patient services, histotechnology, biorepository, and professional patient care on a contractual basis to other institutions, hospitals, and medical facilities. Revenues are recognized over time as the services are rendered. Also included within contractual services are contributions from affiliates of \$18,418,750 and \$21,715,500 for the years ended June 30, 2022 and 2021, respectively, which are recognized as revenue when EVMS has met the conditions of the contribution agreement.

(o) Derivative Instruments

EVMS utilizes derivative financial instruments to reduce its exposure to cash flow risks from changes in interest rates, specifically, variable interest rates. EVMS is exposed to credit losses in the event of nonperformance by the counterparty to the interest rate swap; however, the counterparty is a major financial institution, and the risk of loss due to nonperformance is considered remote. Interest rate differentials paid or received on the swap are recognized as adjustments to expense in the period earned or incurred. Interest rate swaps are recorded at fair value and reflected as assets or liabilities in the accompanying consolidated balance sheet. Changes in the fair value of interest rate swaps are reflected as nonoperating items in the accompanying consolidated statement of activities and changes in net assets.

(p) Concentration of Credit Risk

Financial instruments, which potentially subject EVMS and its affiliated organization to concentration of credit risk, consist principally of cash, investments, patient receivables, and student notes receivable.

EVMS and its affiliated organization place unrestricted cash and temporary overnight investments with high credit quality financial institutions. EVMS and the EVMS Foundation's endowment assets are allocated between several established, reputable asset management firms and, according to their investment policy, are invested in investment-grade instruments. The asset management firms are independent of the funds' trustees who review their performance on a periodic basis.

(q) Long-Lived Assets

Long-lived assets, such as property, plant, and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group to be tested for possible impairment, EVMS first compares undiscounted cash flows expected to be generated by that asset or asset group to its carrying amount. If the carrying amount of the long-lived asset or asset group is not recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent that the carrying amount exceeds its fair value. Fair value is determined through various valuation techniques, including discounted cash flow models, quoted market values, and third-party independent appraisals, as considered necessary. There was no impairment recorded in fiscal year 2022 or 2021.

(r) Use of Estimates

The preparation of the consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported

Notes to Consolidated Financial Statements

June 30, 2022 (With summarized financial information as of June 30, 2021)

amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant items subject to such estimates and assumptions include the useful lives of fixed assets, the valuation of implicit and explicit price concessions for patient receivables, the valuation of derivatives, and the valuation of investments. Actual results could differ from those estimates.

(s) Income Taxes

The Internal Revenues Services has determined and informed EVMS by a letter dated January 28, 1972 that it qualifies as a not-for-profit corporation under Section 501(c)(3) of the Internal Revenue Code (IRS) and is exempt from federal income tax pursuant to Section 501(a) o the IRC. Management is not aware of any course of action or event that has occurred that might adversely affect EVMS' qualified status and believes EVMS is designed and is currently being operated in compliance with the applicable requirements of the IRC. Accordingly, no provision for income taxes is made in the consolidated financial statements. As of June 30, 2022 and 2021, there were no uncertain tax positions.

(t) Release from Restriction

EVMS receives restricted revenue from the Commonwealth of Virginia to fund the construction and purchase of certain real property. As a part of the agreement, EVMS is required to fund a percentage of the cost of the projects. EVMS' share of the cost is funded through fundraising and the issuance of long-term debt. The restriction on the funds received from the Commonwealth of Virginia is being released over the life of the debt EVMS issued to fund the project, in accordance with the donor stipulations specified within the agreement.

(u) Recent Accounting Standard Not Yet Adopted

In February 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2016-02, *Leases (Topic 842)*, intended to improve financial reporting about leasing transactions. The new lease standard requires lessees to put most leases on their balance sheets but recognize expenses on their income statements in a manner similar to today's accounting. The guidance also eliminates today's real estate–specific provisions and changes the sale and leaseback accounting model for all entities. For lessors, the guidance modifies the classification criteria and the accounting for sales-type and direct financing leases. The standard is effective for EVMS as of July 1, 2022. Early adoption is permitted. EVMS is currently evaluating the impact of adoption of the standard on its consolidated financial statements.

(v) Coronavirus Disease (COVID-19)

In March 2020, the World Health Organization declared the outbreak of a novel coronavirus (COVID-19) as a pandemic that continues to spread throughout the United States. In response to the economic impact of COVID-19, the Coronavirus Aid, Relief, and Economic Security (CARES) Act was enacted on March 27, 2020 and included a variety of relief provisions for businesses and individuals.

EVMS was awarded \$0 and \$1,854,791 during fiscal years 2022 and 2021, respectively, from the Department of Education in CARES Act funds to award aid to qualifying students under Section 18004(a)(1) and to help with additional costs incurred by the institution resulting from

Notes to Consolidated Financial Statements

June 30, 2022 (With summarized financial information as of June 30, 2021)

COVID-19. EVMS recognized \$875,955 and \$652,362 during fiscal years 2022 and 2021, respectively, which is recorded within federal grants and contracts in the accompanying consolidated statement of activities and changes in net assets.

EVMS also received \$0 and \$870,272 during fiscal years 2022 and 2021, respectively, from the Commonwealth of Virginia for Coronavirus Relief Funding to aid in additional expenses incurred. EVMS recognized \$0 and \$1,742,175 during fiscal years 2022 and 2021, respectively, which is recorded within state appropriations in the accompanying consolidated statement of activities.

EVMS MG received \$130,774 and \$0 during fiscal years 2022 and 2021 under the CARES Act Provider Relief fund to aid in lost patient service revenue and additional expenses incurred. Given the current financial impact as well as the government aid received, management feels that much of the financial risk associated with COVID-19 has been mitigated.

(w) Subsequent Events

EVMS has evaluated subsequent events from the consolidated balance sheet date through October 27, 2022, the date at which the consolidated financial statements were available to be issued, and determined there are no other items to disclose.

(3) Cash and Cash Equivalents

Cash and cash equivalents at June 30 are summarized as follows:

	-	2022	2021
EVMS EVMS MG	\$	111,696,780 18,934,281	110,740,038 13,764,614
	- \$_	130,631,061	124,504,652

Notes to Consolidated Financial Statements

June 30, 2022 (With summarized financial information as of June 30, 2021)

(4) Operating Investments and Restricted Cash and Investments

(a) Operating investments at June 30 comprised the following:

	_	2022	2021
Money market funds	\$	3,689,881	3,095,082
Equity securities		24,818	266,024
Certificates of deposit		3,748,516	4,552,893
Mutual funds – fixed income		5,911,822	5,383,105
Corporate bonds		11,197,621	8,419,803
Agency mortgage-backed securities		2,154,833	961,583
U.S. Treasury securities		4,875,331	9,408,742
Municipal bonds		4,292,877	5,089,211
Equity method investment	_	417,978	1,897,877
Total operating investments		36,313,677	39,074,320
Less amounts available for current obligations	_	(17,509,494)	(21,093,703)
Long-term operating investments	\$	18,804,183	17,980,617

(b) Restricted cash and investments at June 30 comprised the following:

	 2022	2021
Restricted for parking garage operations – cash	\$ 3,392,693	3,147,709
Restricted for student loans – cash	1,561,589	1,731,150
Restricted for cash balance pension plan – equities	1,898,663	1,816,883
Restricted for interest, debt retirement, and construction per trust indentures: General Revenue Bonds, Series 2006:		
Interest fund – money market funds	7,843	12,935
Principal fund – money market funds	 326,863	315,011
Total Bonds, Series 2006	 334,706	327,946
General Revenue Refunding Bonds, Series 2010:		
Interest fund – money market funds	8,983	50,578
Principal fund – money market funds	 297,544	285,842
Total Bonds, Series 2010	 306,527	336,420

Notes to Consolidated Financial Statements

June 30, 2022

(With summarized financial information as of June 30, 2021)

	-	2022	2021
General Revenue Bonds, Series 2010: Interest fund – money market funds Principal fund – money market funds	\$	7,324 729,276	17,817 729,189
Total Bonds, Series 2010	-	736,600	747,006
General Revenue Bonds, Series 2011: Interest fund – money market funds Principal fund – money market funds	-	7,188 291,710	44,270 291,676
Total Bonds, Series 2011	-	298,898	335,946
General Revenue Bonds, Series 2018: Interest fund – money market funds Principal fund – money market funds Capitalized interest fund – money market funds	-	30,571 72,054 —	10,937 25,000 49,703
Total Bonds, Series 2018	_	102,625	85,640
General Revenue Bonds, Series 2021: Capitalized interest fund – money market funds	-	595,858	695,000
Total Bonds, Series 2021	-	595,858	695,000
Total restricted for interest, debt retirement, and construction per trust indentures	-	2,375,214	2,527,958
Total restricted cash and investments	\$_	9,228,159	9,223,700

Notes to Consolidated Financial Statements

June 30, 2022 (With summarized financial information as of June 30, 2021)

(5) Accounts Receivable, Net

At June 30, accounts receivable comprised the following:

	 2022	2021
Patient accounts receivable	\$ 8,425,727	10,194,520
Sponsored programs receivables:		
Grants and contracts – federal	5,461,844	4,605,095
Grants and contracts – private	192,629	90,612
Grants and contracts – state	 87,569	101,713
Total sponsored programs receivables	5,742,042	4,797,420
Local hospitals, net	9,933,529	4,997,244
Parking	132,797	337,698
Tuition receivable, net	5,442,157	3,604,055
Other, net	 937,653	931,272
Total accounts receivable, net	\$ 30,613,905	24,862,209

(6) Fair Value Measurements

EVMS uses valuation approaches that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. EVMS determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels:

- Level 1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date
- Level 2 Inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability
- Level 3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that
 observable inputs are not available, thereby allowing for situations in which there is little, if any, market
 activity for the asset or liability at the measurement date.

Notes to Consolidated Financial Statements

June 30, 2022 (With summarized financial information as of June 30, 2021)

The following tables present assets and liabilities that are measured at fair value on a recurring basis at

June 30:

	-	Total as of June 30, 2022	Level 1	Level 2	Level 3
Assets:					
Restricted cash and investments:					
Cash and cash equivalents	\$	7,343,596	7,343,596	_	_
Equity securities		1,884,563	1,884,563	_	_
Operating investments:					
Money market funds		3,689,881	3,689,881	_	_
Equity securities		24,818	24,818	_	_
Certificates of deposit		3,748,516	_	3,748,516	_
Mutual funds – fixed income		5,911,822	5,911,822	_	_
Corporate bonds		11,197,621	_	11,197,621	_
Agency mortgage-backed					
securities		2,154,833	_	2,154,833	_
U.S. Treasury securities		4,875,331	_	4,875,331	_
Municipal bonds		4,292,877	_	4,292,877	_
Beneficial interest in net					
assets of affiliate		164,355,934			164,355,934
Total assets at fair	_				
value	\$	209,479,792	18,854,680	26,269,178	164,355,934
	Ť	,,		,0,0	,,,
Liability:					
Interest rate swaps	\$	(278,607)	_	(278,607)	—

(Continued)

Notes to Consolidated Financial Statements

June 30, 2022

(With summarized financial information as of June 30, 2021)

	-	Total as of June 30, 2021	 Level 1	_	Level 2	Level 3
Assets:						
Restricted cash and investments:						
Cash and cash equivalents	\$	7,488,649	7,488,649		—	_
Equity securities		1,735,051	1,735,051		_	_
Operating investments:						
Money market funds		3,095,082	3,095,082		_	_
Equity securities		266,024	266,024		_	_
Certificates of deposit		4,552,893	_		4,552,893	_
Mutual funds – fixed income		5,383,105	5,383,105		—	_
Corporate bonds		8,419,803	_		8,419,803	_
Agency mortgage-backed						
securities		961,583	_		961,583	_
U.S. Treasury securities		9,408,742	_		9,408,742	_
Municipal bonds		5,089,211	_		5,089,211	_
Beneficial interest in net						
assets of affiliate	_	179,232,604	 	_		179,232,604
Total assets at fair						
value	\$_	225,632,747	 17,967,911	=	28,432,232	179,232,604
Liability:						
Interest rate swaps	\$	(1,916,403)	—		(1,916,403)	—

The following methods and assumptions were used to estimate the fair value of each class of financial instruments:

- Cash and cash equivalents and money market funds: Consist of cash and short-term money market funds, which are valued at \$1 per share, which is the price the shares trade at in an active market
- Mutual funds: Valued at the daily quoted net asset value of shares held, which is based on the quoted market prices of the underlying assets of the funds
- Equity securities: Valued using quoted prices from the exchanges upon which the securities actively trade
- Agency mortgage-backed securities, U.S. Treasury securities, municipal bonds, corporate bonds, asset-backed securities, and certificates of deposit: Valued based upon proprietary valuation models that may consider market characteristics, such as benchmark yield curves, option-adjusted spreads, credit spreads, estimated default rates, coupon rates, anticipated timing of principal repayments, underlying collateral, and other security features in order to estimate relevant cash flows, which are discounted to fair value
- Beneficial interest in net assets of affiliate: Reported at fair value, based on the value of the underlying assets, which approximates the present value of future income

Notes to Consolidated Financial Statements

June 30, 2022 (With summarized financial information as of June 30, 2021)

 Interest rate swaps (note 9): The fair value of the interest rate swaps is determined using pricing models that consider assumptions, including time value, interest rates, and yield curves, as well as other relevant economic measures.

EVMS' accounting policy is to recognize transfers between levels of the fair value hierarchy on the date of the event or change in circumstances that caused the transfer. There were no transfers into or out of Level 1, Level 2, or Level 3 for the years ended June 30, 2022 or 2021.

(7) Property, Plant, and Equipment, Net

At June 30, property, plant, and equipment consisted of the following:

	-	2022	2021
Land	\$	2,969,342	2,969,342
Land improvements		9,409,623	9,409,623
Buildings and improvements		279,644,553	274,982,754
Equipment		94,145,665	89,735,106
Construction in progress	-	18,066,835	10,327,966
		404,236,018	387,424,791
Less accumulated depreciation and amortization	-	(198,747,695)	(187,052,138)
Total property, plant, and equipment, net	\$	205,488,323	200,372,653

Depreciation and amortization expenses related to property, plant, and equipment for the years ended June 30, 2022 and 2021 were \$12,396,594 and \$11,811,806, respectively.

(8) Lines of Credit

EVMS has a \$10,000,000 unsecured line of credit facility with a bank. Under the terms of the agreement, interest is payable at one-month London Inter-Bank Rate (LIBOR) plus 1% (3.13% at June 30, 2022). The line of credit was not utilized during the years ended June 30, 2022 and 2021; and expires on January 9, 2023.

EVMS MG has a \$3,000,000 line of credit facility with a bank, which is subject to semiannual review and expires on November 30, 2022. This facility is collateralized by certain accounts receivable. Interest is payable at the one-month LIBOR plus 1.50% (2.95% at June 30, 2022). No amounts were outstanding under the line of credit at June 30, 2022 or 2021.

Notes to Consolidated Financial Statements

June 30, 2022 (With summarized financial information as of June 30, 2021)

(9) Long-Term Debt

At June 30, long-term debt consisted of bonds payable and related interest rate swap agreements as follows:

	_	2022	2021	
Bonds (property and equipment fund):				
General Revenue Bonds, Series 2006	\$	4,415,000	4,955,000	(A)
General Revenue Bonds, Series 2010		7,000,000	8,250,000	(B)
General Revenue Refunding Bonds, Series 2010		7,025,000	7,515,000	(C)
General Revenue Bonds, Series 2011		6,800,000	7,300,000	(D)
General Revenue Bonds, Series 2018		5,934,203	6,024,572	(E)
General Revenue Bonds, Series 2021	_	7,191,085	3,424,764	(F)
		38,365,288	37,469,336	
Interest rate swaps		278,607	1,916,403	(G)
Less bond issuance costs		(318,973)	(345,609)	
Less current portion	_	(2,943,504)	(2,870,369)	
Noncurrent portion	\$_	35,381,418	36,169,761	

(A) On June 15, 2006, EVMS issued the Series 2006 General Revenue Bonds. The Series 2006 Bonds are secured by a Master Indenture of Trust dated November 15, 1991 between EVMS and U.S. Bank, as trustee, as amended, and supplemented by an Eighth Supplemental Indenture of Trust dated June 1, 2006. The Series 2006 Bonds, maturing on November 15, 2028, are subject to mandatory sinking fund redemption by lot at a redemption price of 100% of the principal amount redeemed plus accrued interest on November 15, 2009 and each November 15 thereafter through 2028. In addition, the bonds are also subject to optional redemption, as described in the Indentures of Trust mentioned above.

On April 1, 2021, EVMS modified the Series 2006 General Revenue Bonds, in accordance with the Eighteenth Supplemental Indenture of Trust, effective April 1, 2021, to reduce the current interest rate payable from 2.95% per annum to 2.13% per annum until principal thereof shall have been paid or provided for in full. Interest is payable semiannually on each May 15 and November 15 at a rate of 2.13% per annum. Mandatory sinking fund payments will be due annually on November 15 as follows:

Fiscal year maturities	Principal amount	Fiscal year maturities	-	Principal amount
2023 2024 2025 2026	\$ 560,000 580,000 605,000 630,000	2027 2028 2029	\$	650,000 680,000 710,000

Notes to Consolidated Financial Statements

June 30, 2022 (With summarized financial information as of June 30, 2021)

(B) On October 29, 2010, EVMS issued the Series 2010 General Revenue Bonds. The Series 2010 Bonds are secured by a Master Indenture of Trust dated November 15, 1991 between EVMS and U.S. Bank, as trustee, as amended, and supplemented by a Tenth Supplemental Indenture of Trust dated October 1, 2010. The Series 2010 Bonds, maturing on November 15, 2027, are subject to mandatory sinking fund redemption by lot at a redemption price of 100% of the principal amount redeemed plus accrued interest on May 15, 2011 and each May 15 and November 15 thereafter through 2027. In addition, the bonds are also subject to optional redemption, as described in the Indentures of Trust mentioned above.

On February 27, 2019, EVMS modified the Series 2010 Bonds, in accordance with the Seventeenth Supplemental Indenture of Trust, dated as of April 1, 2019, to delete the put date, remove the 2010 foundation guarantee, and to modify the floating interest rate from 67% of the sum of one-month LIBOR plus 184 basis points to 79% of the sum of one-month LIBOR plus 85 basis points (1.8% and 0.74% as of June 30, 2022 and 2021, respectively).

Interest is payable semiannually on each November 15 and May 15. Mandatory sinking fund payments will be due annually on November 15 as follows:

Fiscal year maturities	-	Principal amount	Fiscal year maturities	 Principal amount
2023 2024 2025	\$	1,250,000 1,250,000 1,250,000	2026 2027 2028	\$ 1,250,000 1,250,000 750,000

(C) On November 15, 2010, EVMS refunded \$10,000,000 of the Series 2008 Bonds by issuing the Series 2010 General Revenue Refunding Bonds. The Series 2010 Refunding Bonds are secured by a Master Indenture of Trust dated November 15, 1991 between EVMS and U.S. Bank, as trustee, as amended, and supplemented by an Eleventh Supplemental Indenture of Trust dated November 1, 2010. The Series 2010 Refunding Bonds, maturing on November 15, 2032, are subject to mandatory sinking fund redemption by lot at a redemption price of 100% of the principal amount redeemed plus accrued interest on May 15, 2011 and each May 15 and November 15 thereafter through 2032. In addition, the bonds are also subject to optional redemption, as described in the Indentures of Trust mentioned above.

On February 27, 2019, EVMS modified the Series 2010 Refunding Bonds, in accordance with the Seventeenth Supplemental Indenture of Trust, dated as of April 1, 2019, to delete the put date, remove the 2010 foundation guarantee, and to modify the floating interest rate from 67% of the sum of one-month LIBOR plus 169 basis points to 79% of the sum of one-month LIBOR plus 95 basis points (1.90% and 0.82% as of June 30, 2022 and 2021, respectively).

Notes to Consolidated Financial Statements

June 30, 2022 (With summarized financial information as of June 30, 2021)

Interest is payable semiannually on each November 15 and May 15. Mandatory sinking fund payments will be due annually on November 15 as follows:

Fiscal year maturities	 Principal amount	Fiscal year maturities	 Principal amount	Fiscal year maturities	 Principal amount
2023	\$ 510,000	2028	\$ 635,000	2033	\$ 785,000
2024	530,000	2029	660,000		
2025	555,000	2030	690,000		
2026	580,000	2031	720,000		
2027	605,000	2032	755,000		

(D) On November 17, 2011, EVMS issued the Series 2011 General Revenue Bonds. The Series 2011 Bonds are secured by a Master Indenture of Trust dated November 15, 1991 between EVMS and U.S. Bank, as trustee, as amended, and supplemented by a Thirteenth Supplemental Indenture of Trust dated November 1, 2011. The Series 2011 Bonds, maturing on November 15, 2032, are subject to mandatory sinking fund redemption by lot at a redemption price of 100% of the principal amount redeemed plus accrued interest on May 15, 2012 and each May 15 and November 15 thereafter through 2032.

On February 27, 2019, EVMS modified the Series 2011 General Revenue Bonds, in accordance with the Seventeenth Supplemental Indenture of Trust, dated as of April 1, 2019, to delete the put date, remove the 2010 foundation guarantee, and to modify the floating interest rate from 65% of the sum of one-month LIBOR plus 170 basis points to 79% of the sum of one-month LIBOR plus 95 basis points (1.90% and 0.82% as of June 30, 2022 and 2021, respectively).

Interest is payable semiannually on each November 15 and May 15. Mandatory sinking fund payments will be due annually on November 15 as follows:

Fiscal year maturities	Principal amount	Fiscal year maturities	Princ amo	•	al year urities	Principal amount
2023 \$ 2024	500,000 550,000	2029	650	,000	033 \$	750,000
2025 2026	550,000 550,000	2030 2031	700	,000 ,000		
2027	600,000	2032	700	,000		

(E) On December 12, 2018, EVMS issued the Series 2018 General Revenue Bonds. The Series 2018 Bonds are secured by a Master Indenture of Trust dated November 15, 1991 between EVMS and U.S. Bank, as trustee, as amended, and supplemented by a Fourteenth Supplemental Indenture and Master Indenture dated November 1, 2018. The Series 2018 Bonds, maturing November 15, 2038, are subject to mandatory sinking fund redemption by lot at a redemption price of 100% of the principal amount redeemed, plus accrued interest on May 15, 2019 and each May 15 and November 15, thereafter through 2038.

Notes to Consolidated Financial Statements

June 30, 2022 (With summarized financial information as of June 30, 2021)

Interest is payable semiannually on each May 15 and November 15 at a rate of 3.46% per annum. Mandatory sinking fund payments will be due annually on November 15 as follows:

Fiscal year maturities	Principal amount	Fiscal year maturities	Principal amount	Fiscal year maturities	Principal amount
2023 \$	121,651	2029 \$	\$ 290,776	2035 \$	483,638
2024	124,618	2030	350,118	2036	501,440
2025	160,223	2031	341,217	2037	519,243
2026	192,862	2032	359,019	2038	540,012
2027	201,763	2033	382,756	2039	557,815
2028	249,237	2034	468,802		

(F) On June 1, 2021, EVMS issued the Series 2021 General Revenue Bonds. The Series 2021 Bonds are secured by a Master Indenture of Trust dated November 15, 1991 between EVMS and U.S. Bank, as trustee, as amended, and supplemented by a Fourteenth Supplemental Indenture and Master Indenture dated June 1, 2006. The Series 2021 Bonds, maturing November 15, 2040, are subject to mandatory sinking fund redemption by lot at a redemption price of 100% of the principal amount redeemed, plus accrued interest on November 15, 2021 and each May 15 and November 15, thereafter through 2040.

Interest is payable semiannually on each May 15 and November 15 at a rate of 2.20% per annum. Mandatory sinking fund payments will be due annually on November 15 as follows:

Fiscal year maturities	 Principal amount	Fiscal year maturities	 Principal amount	Fiscal year maturities	 Principal amount
2023 2024 2025 2026 2027 2028 2029	\$ 99,876 99,876 99,876 99,876 99,876 99,876 199,752	2030 2031 2032 2033 2034 2035 2036	\$ 477,408 489,393 499,381 511,366 521,354 533,339 545,324	2037 2038 2039 2040 2041	\$ 557,309 569,294 583,277 595,262 609,248

(G) EVMS has entered into interest rate swap contracts for its variable rate debt to minimize the effect of changes in LIBOR. The terms of the related interest rate swap contracts are as follows:

The Series 2010 General Revenue Bonds bear interest at 79% of one-month LIBOR plus 85 basis points (1.8% and 0.74% as of June 30, 2022 and 2021, respectively). The related interest rate swap contract has a current notional principal amount of \$7,000,000, under which EVMS pays interest at 3.07% and receives interest at 79% of one-month LIBOR plus 85 basis points. The cumulative unrealized loss of \$57,055 and \$496,963 as of June 30, 2022 and 2021, respectively, from the changes in the swap contract's fair value is included in long-term debt. The swap will expire on November 15, 2027.

Notes to Consolidated Financial Statements

June 30, 2022 (With summarized financial information as of June 30, 2021)

The Series 2010 General Revenue Refunding Bonds bear interest at 79% of one-month LIBOR plus 95 basis points 1.8% and 0.82% as of June 30, 2022 and 2021, respectively). The related interest rate swap contract has a current notional principal amount of \$7,025,000, under which EVMS pays interest at 3.28% and receives interest at 79% of one-month LIBOR plus 95 basis points. The cumulative unrealized loss of \$166,838 and \$790,558 as of June 30, 2022 and 2021, respectively, from the changes in the swap contract's fair value is included in long-term debt. The swap will expire on November 15, 2032.

The Series 2011 General Revenue Bonds bear interest at 79% of one-month LIBOR plus 95 basis points (1.9% and 0.82% as of June 30, 2022 and 2021, respectively). The related interest rate swap contract has a current notional principal amount of \$6,800,000, under which EVMS pays interest at 2.99% and receives interest at 79% of one-month LIBOR plus 95 basis points. The cumulative unrealized loss of \$54,763 and \$628,883 as of June 20, 2022 and 2021, respectively, from the changes in the swap contract's fair value is included in long-term debt. The swap will expire on November 15, 2032.

Annual changes in the swap contracts' fair value are included in nonoperating items in the accompanying consolidated statement of activities.

Pursuant to the terms of the Indentures of Trust, EVMS is required to comply with certain covenants regarding payment of bonds, pledging of revenues, the operations of EVMS, insurance, accounting and financial statements, limitations on liens and the incurrence of additional indebtedness, and the sale, lease, or other disposition of assets. EVMS was in compliance with its covenants for the fiscal years ended June 30, 2022 and 2021. The Series 2006 Bonds are equally and ratably secured by an unconditional guaranty of EVMS Foundation and by security interest in revenue granted by EVMS. The Series 2010, Series 2011, Series 2018, and Series 2021 Bonds are equally and ratably secured by security interest in revenue granted by EVMS.

The aggregate maturities of long-term debt for each of the five fiscal years subsequent to June 30, 2022 are as follows:

2023	\$	2,943,504
2024		3,136,392
2025		3,222,539
2026		3,305,675
2027		3,409,711
Thereafter	_	22,347,467
	\$	38,365,288

Notes to Consolidated Financial Statements

June 30, 2022 (With summarized financial information as of June 30, 2021)

(10) Leases

EVMS has several noncancelable operating leases, primarily for buildings and medical and office equipment, which expire over the next five years. These leases generally contain renewal options for periods ranging from one to five years. Rental expense for operating leases for the years ended June 30, 2022 and 2021 was \$2,407,504 and \$2,951,119, respectively.

Future minimum lease payments under noncancelable operating leases (with initial or remaining lease terms in excess of one year) are as follows:

Year ending June 30:	
2023	\$ 1,431,274
2024	1,040,499
2025	842,800
2026	471,918
2027	200,551
Thereafter	 29,640
Total minimum operating	
lease payments	\$ 4,016,682

(11) Grant Deposits

At June 30, grant deposits for sponsored research consisted of the following:

	<u> </u>	2022	2021
Federal grants	\$	429,456	625,210
State and local grants		552,811	1,202,059
Private gifts and grants		419,907	226,773
Total grant deposits	\$	1,402,174	2,054,042

Grant deposits represent amounts received for various grants and contracts that have not been expended at June 30, 2022 and 2021. If amounts are not expended per agreement, they will be refunded to the grantors, as required.

(12) Related Party (Affiliate) Transactions

١

Various donors contributed funds to the EVMS Foundation for the purpose of establishing loan funds for EVMS students. EVMS manages the award and subsequent collection of these loans from EVMS students on behalf of the EVMS Foundation. The amount of loan funds held for the EVMS Foundation at June 30, 2022 and 2021 was \$980,336 and \$962,068, respectively.

Notes to Consolidated Financial Statements

June 30, 2022

(With summarized financial information as of June 30, 2021)

At June 30, 2022 and 2021, accounts receivable from affiliate were due from the EVMS Foundation in the amount of \$1,566,449 and \$230,784, respectively. This receivable is secured by the EVMS Foundation's investments.

(13) State Appropriations

EVMS receives state appropriated funds annually. A summary of the programs supported for the years ended June 30 is as follows:

		2022	2021
Education	\$	22,892,944	22,893,188
Indigent care		6,158,108	6,158,108
Family medicine		658,597	658,597
Medical modeling and simulation		506,313	412,811
Higher education equipment trust fund		400,159	723,789
Capital maintenance reserve		322,485	180,584
Capital projects – new construction		520,450	20,262,457
Virginia Area Health Education Center		60,620	60,620
Coronavirus Relief Funding	_		1,742,175
	\$	31,519,676	53,092,329

(14) Functional Expenses by Natural Classification

EVMS allocates its expenses on a functional basis among its various programs and supporting services. Expenses that can be identified with a specific program or supporting service are allocated directly. Other expenses that are common to several functions are allocated using cost allocation methods, including square footage, facility usage, and time and attendance. The expenses allocated include depreciation and amortization, salaries and wages, benefits, payroll taxes, professional services, office expenses, information technology, interest, insurance, and other.

Expenses are reported in the consolidated statement of activities in functional categories. Expenses by natural category for the years ended June 30 were as follows:

	For the year ended June 30, 2022								
	Undergraduate instruction	Graduate instruction	Research	Patient services	Academic support	Institutional support	Auxiliary services	Patient services support	Totals
Operating expenses:									
Salaries and wages	42,582,137	24,300,150	8,794,700	42,181,403	7,304,502	16,882,598	5,678,717	4,090,474	151,814,681
Fringe benefits	7,227,022	6,911,914	1,578,113	6,322,306	1,503,983	3,405,905	1,394,222	901,644	29,245,109
Operating supplies	2,970,650	387,502	1,218,760	4,257,901	1,406,867	641,868	116,218	110,220	11,109,986
Contractual services	3,286,984	317,193	7,445,775	1,548,845	1,103,335	7,176,568	3,233,599	1,344,934	25,457,233
General expenses	4,910,360	634,844	3,876,908	7,436,900	(1,114,917)	2,255,728	5,276,227	1,559,314	24,835,364
Depreciation and amortization	1,790,346	14,747	382,111	516,498		(402,942)	9,637,808	458,026	12,396,594
Total operating expenses	62,767,499	32,566,350	23,296,367	62,263,853	10,203,770	29,959,725	25,336,791	8,464,612	254,858,967

Notes to Consolidated Financial Statements

June 30, 2022 (With summarized financial information as of June 30, 2021)

		For the year ended June 30, 2021							
	Undergraduate instruction	Graduate instruction	Research	Patient services	Academic support	Institutional support	Auxiliary services	Patient services support	Totals
Operating expenses:									
Salaries and wages	\$ 42,330,288	22,987,503	8,421,900	50,495,294	7,352,509	13,927,078	5,491,798	4,125,079	155,131,449
Fringe benefits	6,726,310	6,276,067	1,459,824	6,168,010	1,420,335	3,258,086	1,249,004	981,121	27,538,757
Operating supplies	2,574,443	390,754	1,196,318	4,519,094	1,379,054	576,135	97,186	180,899	10,913,883
Contractual services	2,836,517	293,498	5,803,928	2,110,854	778,187	5,932,894	2,710,544	1,264,040	21,730,462
General expenses	3,431,477	257,912	2,941,858	5,527,426	(1,220,546)	1,482,043	5,609,142	1,650,663	19,679,975
Depreciation and amortization	1,662,469	17,586	393,612	561,101		274,869	8,414,800	487,369	11,811,806
Total operating expenses	\$59,561,504	30,223,320	20,217,440	69,381,779	9,709,539	25,451,105	23,572,474	8,689,171	246,806,332

(15) Retirement Plan

Substantially all of the salaried personnel of EVMS are eligible after specified periods of employment to participate in qualified tax-deferred annuity plans under Sections 403(b) and 401(a) of the IRC. EVMS' contributions to the plans are based on percentages of qualified employee earnings. EVMS contributions to this program were \$5,440,724 and \$5,424,938 for the fiscal years ended June 30, 2022 and 2021, respectively.

(16) Commitments and Contingencies

Amounts received and expended by EVMS under various federal and state programs are subject to audit by various federal and state agencies. In the opinion of management, audit adjustments, if any, will not have a significant effect on the consolidated financial position of the School.

EVMS is subject to various legal proceedings and claims, which arise in the ordinary course of its business. Appropriate provision has been made for possible losses, and in the opinion of management, the ultimate resolution of these matters will not have a material adverse effect on the consolidated financial position, results of activities, or liquidity of the School.

Notes to Consolidated Financial Statements

June 30, 2022

(With summarized financial information as of June 30, 2021)

(17) Concentrations of Credit Risk

EVMS MG grants credit without collateral to its patients, most of whom are local residents and are insured under third-party payor agreements. The approximate mix of receivables from patients and third-party payors by type of payor, for the years ended June 30, is as follows:

	2022	2021	
Self-pay	27 %	24 %	
Medicare	17	17	
Medicaid	21	20	
HMO (none more than 10%)	12	12	
Commercial	8	9	
Anthem	8	10	
Other	7	8	
	100 %	100 %	

(18) Sources of Patient Service Revenue

Patient care service revenue is due from patients, third-party payors (including health insurers and government payors), and others and includes variable consideration for retroactive revenue adjustments due to settlement of audits, reviews, and investigations. Generally, EVMS MG bills the patients and third-party payors after the services are performed. Revenue is recognized as the performance obligations are satisfied.

Performance obligations are determined based on the nature of the services provided. Revenue for performance obligations satisfied over time is recognized based on actual charges incurred in relation to total expected (or actual) charges. EVMS MG believes that this method provides a faithful depiction of the transfer of services over the term of the performance obligation based on the inputs needed to satisfy the obligation. Generally, performance obligations satisfied over time relate to patients receiving inpatient acute care services or patients receiving services in our outpatient centers. EVMS MG measures the performance obligation at the time of completion of each inpatient or outpatient encounter.

The transaction price is based on standard charges for goods and services provided, reduced by contractual adjustments provided to third-party payors, discounts provided to uninsured patients in accordance with EVMS MG's policy, or implicit price concessions provided to uninsured patients. Estimates of contractual adjustments and discounts are based on contractual agreements, its discount policies, and historical experience. Estimates of implicit and explicit price concessions are based on its historical collection experience with this class of patients.

Notes to Consolidated Financial Statements

June 30, 2022 (With summarized financial information as of June 30, 2021)

EVMS MG has agreements with third-party payors to provide for payments at amounts less than established charges. A summary of the payment arrangements with major third-party payors follows:

Medicare. Certain inpatient acute care services are paid at prospectively determined rates per discharge based on clinical, diagnostic, and other factors. Certain services are paid based on cost-reimbursement methodologies subject to certain limits. Physician services are paid based upon established fee schedules. Outpatient services are paid using prospectively determined rates.

Medicaid. Reimbursements for Medicaid services are generally paid at prospectively determined rates per discharge, per occasion of service, or per covered member.

Other. Payment agreements with certain commercial insurance carriers, health maintenance organizations, and preferred provider organizations provide for payment using prospectively determined rates per discharge, discounts from established charges, and prospectively determined daily rates.

Laws and regulations concerning government programs, including Medicare and Medicaid, are complex and subject to varying interpretation. Compliance with such laws and regulations may also be subject to future government review and interpretation as well as significant regulatory action, including fines, penalties, and potential exclusion from the related programs. There can be no assurance that regulatory authorities will not challenge EVMS MG's compliance with these laws and regulations, and it is not possible to determine the impact (if any) such claims, or penalties would have upon EVMS MG. In addition, the contracts EVMS MG has with commercial payors also provide for retroactive audit and review of claims.

Settlements with third-party payors for retroactive revenue adjustments due to audits, reviews, or investigations are considered variable consideration and are included in the determination of the estimated transaction price for providing patient care. These settlements are estimated based on the terms of the payment agreement with the payor, correspondence from the payor and EVMS MG's historical settlement activity, including an assessment to ensure that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the retroactive adjustment is subsequently resolved. Estimated settlements are adjusted in future periods as adjustments become known (that is, new information becomes available), or as years are settled or are no longer subject to such audits, reviews, and investigations.

Consistent with EVMS MG's mission, care is provided to patients regardless of their ability to pay. Therefore, EVMS MG has determined it has provided implicit price concessions to uninsured patients and other uninsured balances (for example, copays and deductibles). The implicit price concessions included in estimating the transaction price represents the difference between amounts billed to patients and the amounts expected to collect based on its collection history with those patients.

Generally, patients who are covered by third-party payors are responsible for related deductibles and coinsurance, which vary in amount. EVMS MG also provides services to uninsured patients and offers those uninsured patients a discount, either by policy or law, from standard charges. EVMS MG estimates the transaction price for patients with deductibles and coinsurance and from those who are uninsured based on historical experience and current market conditions. The initial estimate of the transaction price is determined by reducing the standard charge by any contractual adjustments, discounts, and implicit price

Notes to Consolidated Financial Statements

June 30, 2022 (With summarized financial information as of June 30, 2021)

concessions based on historical collection experience. Subsequent changes to the estimate of the transaction price are generally recorded as adjustments to patient service revenue in the period of the change. Subsequent determined to be the result of an adverse change in the patient's ability to pay are recorded as bad debt expense.

EVMS MG has determined that the nature, amount, timing, and uncertainty of revenue and cash flows are affected by the following factors:

- Payors (for example, Medicare, Medicaid, managed care or other insurance, patient) have different reimbursement and payment methodologies
- Length of the patient's service or episode of care
- Method of reimbursement
- Medical specialty that provided the service

(19) Liquidity and Availability

Financial assets available for general expenditure within one year of the balance sheet date are as follows:

	-	2022	2021
Total assets	\$	588,002,946	587,470,615
Less:			
Restricted cash and investments		9,228,159	9,223,700
Property, plant, and equipment, net		205,488,323	200,372,653
Noncurrent operating investments		18,804,183	17,980,617
Notes receivable from students		2,314,507	1,965,813
Interest in net assets of affiliate		164,355,934	179,232,604
Other long-term assets	_	4,255,384	4,200,428
Financial assets available within one year	\$_	183,556,456	174,494,800

EVMS manages its financial assets to be available as its operating expenditures, liabilities, and other obligations come due. Although the noncurrent investments disclosed in the table above are intended to be held long-term, EVMS could utilize those investments within the next year if deemed necessary. As described in note 8, EVMS has available lines of credit in the amounts of \$10 million and \$3 million, with no amounts outstanding at June 30, 2022. The lines of credit expire in January 2023 and November 2022, respectively.

Notes to Consolidated Financial Statements

June 30, 2022 (With summarized financial information as of June 30, 2021)

(20) Department of Education Financial Responsibility Standards

EVMS participates in federal Title IV student financial assistance programs, which require it to meet standards of financial responsibility based on criteria determined by the U.S. Department of Education (ED), as set forth in 34 CFR Subpart 668.171. The criteria for private institutions include the annual calculation by ED of a financial responsibility composite score, as further outlined in 34 CFR Subpart 668.172, using audited financial statements submitted through ED's eZ-Audit system. The composite score has been and will continue to be based on three ratios: Primary Reserve, Equity, and Net Income. Inputs to these ratios as of and for the year ended June 30, 2022 are bolded below and include (a) elements directly from the accompanying consolidated financial statements and related other notes to the consolidated financial statements, as well as (b) certain other financial data. Additional financial information, which is not bolded, has also been presented to facilitate understanding and reconciliation of such data elements to the accompanying consolidated financial statements and related other notes.

	Data element		Amount
(a)	Property, plant and equipment, net: pre-implementation Property, plant and equipment, net: post-implementation without	\$	119,528,294
	outstanding debt for original purchase		67,893,193
	Construction in progress, net: post-implementation	-	18,066,835
	Total property, plant and equipment, net on Consolidated Balance Sheet	\$	205,488,322
	Pre-implementation is defined as before July 1, 2019, and represents amounts capitalized as of June 30, 2019. Post-implementation is defined as July 1, 2019 and after		
(b)	Long-term debt, net: pre-implementation Long-term debt, net: post-implementation	\$	31,133,837 7,191,085
	Total long-term debt, net on Consolidated Balance Sheet	\$	38,324,922
	All long-term debt, net as of July 1, 2019 is classified as pre-implementation debt		
(c)	Total Net assets with donor restrictions - restricted in perpetuity Total Net assets with donor restrictions - not restricted in perpetuity	\$	85,450,721 185,078,664
		-	100,070,004
	Total net assets with donor restrictions on Consolidated Balance Sheet	\$	270,529,385

Appendix A

EASTERN VIRGINIA MEDICAL SCHOOL AND AFFILIATED ORGANIZATION

Schedule of Financial Responsibility Data

As of and for the year ended June 30, 2022

Source of data element in consolidated financial statements or notes to Financial data element consolidated financial statements		 Amount used for ratio
Primary Reserve Ratio:		
Numerator – Expendable Net Assets Ratio Inputs:		
Net assets without donor restrictions	Consolidated Balance Sheet	\$ 225,255,516
Net assets with donor restrictions	Consolidated Balance Sheet	270,529,385
Property, plant and equipment, net: pre-implementation	Note 20 – Financial Responsibility Standards	119,528,294
Property, plant and equipment, net: post-implementation with outstanding debt for original purchase	Note 20 – Financial Responsibility Standards	67,893,193
Construction in progress, net: post-implementation	Note 20 – Financial Responsibility Standards	18,066,835
Long-term debt, net: pre-implementation	Note 20 – Financial Responsibility Standards	31,133,837
Long-term debt, net: post-implementation	Note 20 – Financial Responsibility Standards	7,191,085
Net assets with donor restrictions: restricted in perpetuity	Note 20 – Financial Responsibility Standards	85,450,721
Denominator – Total Expenses and Losses Without Donor Restrictions:		
Total operating expenses	Consolidated Statement of Activities	254,858,967
Unrealized losses from investments, net	Consolidated Statement of Activities	(2,977,259)
Equity Ratio:		
Numerator – Modified Net Assets Inputs:		
Net assets without donor restrictions	Consolidated Balance Sheet	\$ 225,255,516
Net assets with donor restrictions	Consolidated Balance Sheet	270,529,385
Denominator – Modified Assets Inputs:		
Total assets	Consolidated Balance Sheet	588,002,946
Net Income Ratio:		
Numerator – Change in Net Assets Without Donor Restrictions Denominator: Total Revenue and Gains Without Donor Restrictions:	Consolidated Statement of Activities	\$ 20,940,578
Total operating revenues and support without donor restrictions	Consolidated Statement of Activities	277,139,007
Unrealized losses from investments, net	Consolidated Statement of Activities	(2,977,259)
Gain on change in fair value of interest rate swaps	Consolidated Statement of Activities	1,637,797
		.,,

See accompanying independent auditors' report.



KPMG LLP Suite 1900 440 Monticello Avenue Norfolk, VA 23510

Independent Auditors' Report on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance With *Government Auditing Standards*

The Board of Visitors Eastern Virginia Medical School:

We have audited, in accordance with the auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States, the consolidated financial statements Eastern Virginia Medical School and Affiliated Organization (EVMS), which comprise the consolidated balance sheet as of June 30, 2022, and the related consolidated statements of activities and changes in net assets, and cash flows for the year then ended, and the related notes to the consolidated financial statements, and have issued our report thereon dated October 28, 2022.

Our report includes a reference to other auditors who audited the financial statements of Eastern Virginia Medical School Foundation (EVMS Foundation), as described in our report on EVMS' consolidated financial statements. The financial statements of EVMS Foundation were not audited in accordance with *Government Auditing Standards*, and accordingly, this report does not include reporting on internal control over financial reporting or compliance and other matters associated with EVMS Foundation.

Report on Internal Control Over Financial Reporting

In planning and performing our audit of the consolidated financial statements, we considered EVMS' internal control over financial reporting (internal control) as a basis for designing audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the consolidated financial statements, but not for the purpose of expressing an opinion on the effectiveness of EVMS' internal control. Accordingly, we do not express an opinion on the effectiveness of EVMS' internal control.

A deficiency in internal control exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, misstatements on a timely basis. A material weakness is a deficiency, or a combination of deficiencies, in internal control, such that there is a reasonable possibility that a material misstatement of the entity's financial statements will not be prevented, or detected and corrected, on a timely basis. A significant deficiency is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses or significant deficiencies may exist that were not identified.

Report on Compliance and Other Matters

As part of obtaining reasonable assurance about whether EVMS' consolidated financial statements are free from material misstatement, we performed tests of its compliance with certain provisions of laws, regulations,



contracts, and grant agreements, noncompliance with which could have a direct and material effect on the financial statements. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.

Purpose of This Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of EVMS' internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering EVMS' internal control and compliance. Accordingly, this communication is not suitable for any other purpose.



Norfolk, Virginia October 28, 2022